Publication | Closed Access

A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: The TUCC trial

ThrombosisUsual Dose UrokinaseCardiovascular DiseaseMedicineAtherosclerosisPharmacotherapyRandomized TrialTucc TrialPharmacologyCardiologyCoronary Artery DiseaseAcute Myocardial InfarctionMyocardial Infarction